Literature DB >> 21790701

Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.

Huseyin Demirbilek1, Ayfer Alikasifoglu, Nazli E Gonc, Alev Ozon, Nurgun Kandemir.   

Abstract

OBJECTIVE: Intravenous GnRH stimulation test has often been used as gold standard test for the evaluation of hypothalamic-pituitary-gonadal axis in the diagnosis of central precocious puberty (CPP) and in the assessment of pubertal suppression. However, this test is time-consuming, costly and uncomfortable for the patients. We aimed to analyse the validity of single LH sample 90 min after GnRH analogue (GnRHa) administration in the evaluation of gonadotrophin suppression during CPP therapy and to determine a cut-off level for LH indicating adequate suppression.
DESIGN: Prospective study. PATIENTS AND METHODS: One hundred and forty-two patients with CPP were included in this study. Peak LH level during iv GnRH stimulation test after the third dose of GnRHa was compared with LH level 90 min after injection of the 3rd dose of GnRHa.
RESULTS: There was a positive correlation between LH level following a GnRHa injection and peak LH during standard iv GnRH stimulation test (r = 0·83; P < 0·0001). A LH value of 2·5 mIU/ml or less 90 min after GnRHa injection was considered to be the cut-off for the determination of pubertal suppression (sensitivity and specificity was 100% and 88%, respectively). In 117 patients, gonadotrophin suppression was existed according to both GnRHa and iv GnRH tests. In 25 patients, gonadotrophin suppression was not found in the GnRHa test. However, 16 of them were suppressed according to the iv GnRH test.
CONCLUSION: Single LH determination 90 min after GnRHa administration using a cut-off level of 2·5 mIU/ml reflects pubertal suppression with a high sensitivity and specificity. However, this test may fail to show pubertal suppression in some cases. Those patients who appear to be inadequately suppressed should be reassessed using standard iv GnRH stimulation test for optimal dose adjustment.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21790701     DOI: 10.1111/j.1365-2265.2011.04185.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  A Gonadotropin-Releasing Hormone (GnRH) Stimulation Test Before and After GnRH Analogue Treatment for Central Precocious Puberty: Has the GnRH Test been Adequately Simplified?

Authors:  Min Sun Kim; Pyoung Han Hwang; Dae-Yeol Lee
Journal:  Indian J Pediatr       Date:  2015-05-10       Impact factor: 1.967

2.  Clinical and Laboratory Parameters of Gonadotropin-Releasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty.

Authors:  Lívia Grimaldi Abud Fujita; Heloísa Marcelina da Cunha Palhares; Adriana Paula da Silva; Janaíne Machado Tomé; Maria de Fátima Borges
Journal:  Clinics (Sao Paulo)       Date:  2019-11-07       Impact factor: 2.365

3.  Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA).

Authors:  Johanna Olson-Kennedy; Laer H Streeter; Robert Garofalo; Yee-Ming Chan; Stephen M Rosenthal
Journal:  Transgend Health       Date:  2021-02-15

4.  Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.

Authors:  Lindsey Yoojin Chung; Eungu Kang; Hyo-Kyoung Nam; Young-Jun Rhie; Kee-Hyoung Lee
Journal:  J Korean Med Sci       Date:  2021-08-30       Impact factor: 2.153

5.  Is premature thelarche in the first two years of life transient?

Authors:  Ahmet Uçar; Nurçin Saka; Firdevs Baş; Rüveyde Bundak; Hülya Günöz; Feyza Darendeliler
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.